Wednesday, August 5, 2026
← Back to archivePolicy
Policy•STAT News•Aug 5, 2026
Opinion: Tear down the wall between M.D. and D.O. education
background ▾
- •Outcome data from JAMA Surgery and Annals of Internal Medicine demonstrate no significant differences in mortality, readmissions, or patient care quality between M.D. and D.O. physicians, yet residency programs exhibit persistent credential-based bias—30% of vascular surgery programs never consider D.O. applicants versus none reporting the same for M.D. applicants
- •D.O. students face dual financial and administrative burden (two exam series, higher fees, broader applications) to compete for identical residency positions, creating an inequitable pipeline despite equivalent clinical competence
- •Structural reform would require alignment among the LCME, Commission on Osteopathic College Accreditation, NRMP, and residency program directors—a multi-stakeholder coordination challenge with no clear catalyst for change
Policy•STAT News•Aug 5, 2026
Opinion: Something is missing from movies about medical aid in dying
background ▾
- •This is a cultural commentary and opinion piece without breaking pharmaceutical news, regulatory decisions, clinical data, or business developments — it falls outside the scope of actionable pharma industry intelligence
Policy•KFF•Aug 4, 2026
The Future of CDC HIV Prevention Funding for Community Organizations
background ▾
- •CDC ending direct funding to community-based HIV prevention organizations for the first time since the late 1980s, with potentially $230+ million at stake for CBOs nationwide.
- •New funding mechanism through state/local health departments provides no guarantee of CBO support, creating sustainability risk for organizations serving disproportionately affected communities.
- •Decision reflects broader Trump administration policy agenda limiting federal funding for LGBTQ+ and racial/ethnic health disparity programs, despite Congressional opposition to CDC HIV prevention funding cuts.
PrEP
→ Read original articlePolicy•KFF•Aug 4, 2026
The Facts About Medicare Spending
background ▾
- •Medicare Advantage enrollment has more than doubled from 25% to 54% of beneficiaries between 2010-2025, with payments now estimated at 114% of traditional Medicare costs due to higher coding intensity and favorable risk selection
- •Per-beneficiary spending growth in Medicare is projected to accelerate from historical lows (3.1% annually) to 6.0% annually by 2034, driven primarily by population aging and increased service utilization
- •Physician services and outpatient care (Part B) now exceed hospital spending (Part A) in Medicare's budget, with this gap expected to widen—critical for understanding where pharma products (especially physician-administered drugs) fit in overall spending trajectories
Policy•Fierce Biotech•Aug 4, 2026
Fiercest Women in Life Sciences 2026: Nominations open now
background ▾
Market Access
Market Access•Fierce Biotech•Aug 4, 2026
Lisata lays off 72% of staffers, sues Kuva after planned merger falls apart
background ▾
- •Kuva Labs terminated its January-announced acquisition of Lisata after the deal was expected to close in Q3 2024, forcing Lisata to cut 72% of staff and file litigation for breach of merger agreement
- •The merger collapse eliminates a clear commercialization pathway for certepetide, though Catalent's interest in the molecule as an ADC payload (secured October 2025) provides an alternative development avenue
- •Monitor Delaware Court of Chancery proceedings and Lisata's stated pivot to 'alternative strategies'—outcome may dictate certepetide's future and whether Kuva's NanoMark platform moves forward independently
Lisata PharmaceuticalsKuva LabsCatalentcertepetide
→ Read original articleMarket Access•Fierce Biotech•Aug 4, 2026
KKR inks $5.7B deal to take medtech manufacturing giant Integer private
background ▾
- •KKR to acquire Integer Holdings for $5.7B in cash, positioning a major PE firm to control critical medtech contract manufacturing capacity across multiple therapeutic areas
- •Integer generated $1.85B in 2025 revenue with 8% YoY growth, indicating stable demand for its CDMO and device component services in an attractive market segment
KKRInteger HoldingsGoldman Sachs
→ Read original articleMarket Access•Fierce Biotech•Aug 4, 2026
Latigo laces up for $247M IPO to fund non-opioid pain drug rival to Vertex’s Journavx
background ▾
- •Latigo secured $247–285 million IPO funding specifically to advance LTG-001 (Nav1.8 inhibitor) through phase 3 in post-surgical pain, positioning it as a direct competitor to Vertex's Journavx with claimed advantages in efficacy, onset time, and safety profile
- •The company is pursuing a multi-asset strategy with LTG-321 (once-daily dosing for osteoarthritis) and LTG-418 (multiple delivery modalities), betting on differentiated pharmacokinetics to capture chronic-use indications where Journavx may have limitations
- •Phase 3 readouts are not expected until late 2027, leaving significant clinical and regulatory risk; success depends on demonstrating meaningful advantages over an already-approved, first-in-class competitor with established market presence
Latigo BiotherapeuticsVertex PharmaceuticalsWestlake Village BioPartnersLTG-001LTG-321LTG-418
→ Read original articleMarket Access•STAT News•Aug 5, 2026
MRI is standard for diagnosing prostate cancer in most western countries. But most U.S. men don’t get them
background ▾
- •Pre-biopsy MRI is adopted in ~33% of U.S. cases vs. standard of care in Western Europe, Canada, Australia, and U.K., despite identical guideline recommendations since 2020
- •Up to 70% of new U.S. prostate cancer diagnoses are low-grade and clinically insignificant, yet 50%+ receive unnecessary treatment due to systematic biopsy-first approach
- •Barriers to adoption include slow technology diffusion, urologist unfamiliarity with MRI interpretation, and loss of biopsy revenue—representing a significant payer/access opportunity for cost containment and patient harm reduction
Market Access•Endpoints News•Aug 5, 2026
Gilead’s Yeztugo beats forecasts as HIV PrEP franchise exceeds $1B
background ▾
- •Yeztugo Q2 sales of $232M exceeded consensus estimates by ~5%, signaling stronger-than-expected uptake and market penetration
- •HIV PrEP franchise now exceeds $1 billion in annual revenue, establishing Yeztugo as a meaningful commercial contributor to Gilead's portfolio
- •Monitor competitive dynamics with oral PrEP alternatives (Descovy, generic tenofovir/emtricitabine) and emerging long-acting modalities that could pressure pricing or volume growth
Gilead SciencesYeztugocabotegravir/rilpivirine
→ Read original articleClinical Trials
Clinical Trials•Fierce Biotech•Aug 4, 2026
Amgen drops early-stage obesity drug, upping pressure on MariTide
background ▾
- •Amgen has terminated AMG 513 development following an FDA clinical hold, signaling the company's high bar for obesity candidates and confidence in MariTide as its lead asset in this high-value market
- •This is Amgen's second obesity drug discontinuation in 18 months (AMG 786 also scrapped), concentrating pipeline risk on MariTide's phase 3 program and 2026 readouts
- •Monitor MariTide phase 3 results in 2026, particularly weight loss efficacy data, as any setback would leave Amgen without a near-term obesity competitor in a market dominated by Novo Nordisk and Eli Lilly
AmgenAMG 513MariTideAMG 786
→ Read original articleClinical Trials•Fierce Biotech•Aug 4, 2026
Pfizer axes ex-Metsera obesity asset and GIPR prospect in quarterly clearout
background ▾
- •MET-224o, a key asset from Pfizer's $10B Metsera acquisition, is being discontinued based on clinical performance, raising questions about the strategic rationale for that high-priced deal.
- •Pfizer's GIPR antagonist PF-07976016 failed to advance beyond phase 2a, despite plans announced in December 2023 to combine it with the YaoPharma GLP-1 drug—a setback for the dual-mechanism obesity strategy.
- •Monitor berobenatide's phase 3 development closely, as it is now Pfizer's primary obesity asset; the company claims it may offer weight loss comparable to tirzepatide with better GI tolerability and monthly dosing convenience.
PfizerMetseraNovo NordiskMET-224oPF-07976016YP05002
→ Read original articleClinical Trials•Fierce Biotech•Aug 4, 2026
Merck’s $11B anti-TL1A bet delivers 1 win, 1 loss in midphase inflammatory disease trials
background ▾
- •Merck terminated the SSc-ILD program after phase 2 failure with no new safety signals, acknowledging that no anti-cytokine has previously succeeded in this challenging, refractory indication.
- •Tulisokibart achieved phase 2b success in HS and has already demonstrated phase 3 efficacy in UC, positioning it as a potentially significant late-stage asset to mitigate Keytruda patent expiration in 2028.
- •Upcoming phase 2/3 readouts in rheumatoid arthritis (2025) and axial spondyloarthritis (2027) will determine whether TL1A can be validated as a broad immunology node or remains restricted to specific indications.
Merck & Co.Prometheus BiosciencesRochetulisokibartafimkibartduvakitug
→ Read original articleClinical Trials•Fierce Biotech•Aug 4, 2026
Icon inks Anthropic partnership to deploy Claude into clinical trials
background ▾
- •Icon will integrate Claude AI into its Orbis platform to tackle clinical trial enrollment—the single biggest operational bottleneck causing delays in up to 80% of studies—through improved site intelligence and predictive enrollment risk detection.
- •The partnership reflects deepening ties between biopharma and Anthropic, following similar enterprise AI deals with Bristol Myers Squibb and Novartis, positioning Claude as a platform for clinical trial optimization across the industry.
- •Monitor real-world outcomes: Icon's ability to demonstrate measurable reductions in enrollment timelines and trial delays through this deployment will determine whether AI-driven operational optimization becomes a competitive advantage in CRO services.
IconAnthropicBristol Myers Squibb
→ Read original articleClinical Trials•STAT News•Aug 4, 2026
Ebola kills 1,700 in eastern Congo as the fastest-growing outbreak surges
background ▾
- •This Bundibugyo Ebola outbreak is the fastest-growing on record with a death rate exceeding all prior outbreaks, killing 1,700 in ~4 months versus 8 months to reach 1,000 deaths in the 2014–2016 West African epidemic.
- •Clinical trials for post-exposure prophylaxis and vaccines are actively enrolling in Ituri province and internationally, representing critical data generation amid an uncontrolled outbreak with no approved therapeutics or vaccines for Bundibugyo virus.
- •Key uncertainties include outbreak peak timing, efficacy of investigational treatments/vaccines in real-world conditions with 60–70% community spread, and whether security, funding, and healthcare worker availability will sustain trial operations.